Introduction/Overview Ethanol, or ethyl alcohol, is a simple two-carbon alcohol (CH3CH2OH) that represents one of the most widely consumed psychoactive substances globally. Its use spans recreational, cultural, ritualistic, and, to a limited extent, therapeutic contexts. The pharmacology of ethanol is complex, involving non-specific interactions with multiple neuronal systems and a metabolism that follows non-linear kinetics. … Read more

Introduction/Overview Thiopental sodium, a thiobarbiturate derivative, represents a cornerstone agent in the history of intravenous anesthesia. First introduced into clinical practice in the 1930s, it revolutionized anesthetic induction by providing rapid, predictable onset of unconsciousness. Although its use has declined in many settings with the advent of newer agents like propofol, thiopental retains significant clinical … Read more

Introduction/Overview Lithium carbonate represents a cornerstone in the psychopharmacological management of mood disorders, possessing a unique therapeutic profile distinct from other psychotropic agents. Its introduction into modern psychiatry in the mid-20th century marked a pivotal advancement, providing the first effective maintenance treatment for bipolar disorder. The clinical utility of lithium extends beyond acute mania to … Read more

Introduction/Overview Amitriptyline, a prototypical tricyclic antidepressant (TCA), represents a cornerstone agent in psychopharmacology with a complex and multifaceted pharmacological profile. Initially synthesized in the early 1960s, its introduction marked a significant advancement in the treatment of major depressive disorder. Despite the subsequent development of newer antidepressant classes with improved tolerability, such as selective serotonin reuptake … Read more

Introduction/Overview Fluoxetine represents a cornerstone agent in the psychopharmacological armamentarium, being the first selective serotonin reuptake inhibitor (SSRI) approved for clinical use. Its introduction in the late 1980s marked a paradigm shift in the treatment of depression and related disorders, offering an improved tolerability and safety profile compared to the tricyclic antidepressants and monoamine oxidase … Read more

Introduction/Overview Clozapine represents a cornerstone in the psychopharmacological management of severe psychiatric disorders, distinguished by its unique efficacy and complex safety profile. As the prototypical atypical antipsychotic, its development marked a significant departure from conventional neuroleptics, offering therapeutic benefits for patients unresponsive to standard treatments. The clinical importance of clozapine is primarily anchored in its … Read more

Introduction/Overview Chlorpromazine, introduced into clinical practice in the 1950s, represents a landmark therapeutic agent in the history of psychopharmacology. Its discovery and subsequent application fundamentally altered the management of severe psychiatric disorders, facilitating the deinstitutionalization movement and establishing the foundation for modern neuroleptic therapy. As the prototypical typical, or first-generation, antipsychotic, chlorpromazine belongs to the … Read more

Introduction/Overview Haloperidol represents a cornerstone agent in the class of typical antipsychotic medications, primarily employed in the management of psychotic disorders and acute agitation. First synthesized in 1958 by Paul Janssen, its introduction marked a significant advancement in psychopharmacology, offering an alternative to the phenothiazines with a distinct chemical structure and a potentially different side … Read more

Introduction/Overview Levodopa, or L-3,4-dihydroxyphenylalanine (L-DOPA), represents the cornerstone of pharmacological therapy for Parkinson’s disease. Its introduction in the late 1960s revolutionized the management of this neurodegenerative disorder, providing profound symptomatic relief and significantly improving patient quality of life and mortality. As a metabolic precursor to the neurotransmitter dopamine, levodopa is designed to bypass the blood-brain … Read more